Physician profile
Thomas M Graff
NPI 1689665440
$4,207.92
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,305 · 2020: $1,333 · 2021: $491 · 2022: $43.84 · 2023: $18.31 · 2024: $16.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $540.10 | 2019-2024 | Wegovy |
| Pfizer INC. | $532.36 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $524.69 | 2019-2021 | |
| Glaxosmithkline, LLC. | $369.18 | 2019-2021 | |
| Lilly USA, LLC | $338.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $183.52 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.51 | 2019-2021 | |
| Astellas Pharma US INC | $173.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.58 | 2019-2021 | |
| Mylan Specialty L.P. | $138.03 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $135.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $123.62 | 2019-2021 | |
| Abbvie INC. | $101.81 | 2019-2022 | |
| Indivior INC. | $95.13 | 2019-2020 | |
| Amarin Pharma, INC. | $92.69 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.37 | 2020 | |
| Allergan, INC. | $58.71 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $55.16 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $54.53 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $53.21 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.66 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $27.04 | 2019 | |
| Genentech USA, INC. | $25.56 | 2020-2021 | |
| Medical Device Business Services, INC. | $24.17 | 2019 | |
| Shire North American Group INC | $23.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.25 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $22.55 | 2019 | |
| Medtronic Minimed, INC. | $19.00 | 2019 | |
| Radius Health, INC. | $14.33 | 2019 | |
| Lundbeck LLC | $13.77 | 2020 | |
| Circassia INC. | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Graff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.